PORTLAND, Oregon and PUNE, India, January 25, 2017 /PRNewswire/ --
According to a new report published by Allied Market Research, titled, "Chemotherapy-induced Nausea and Vomiting (CINV) Market-Global Opportunity Analysis and Industry Forecast, 2014-2022," the global chemotherapy-induced nausea and vomiting (CINV) market was valued at $1,663 million in 2015, and is estimated to reach $2,659 million by 2022, registering a CAGR of 7.1% during 2016-2022.
(Logo: http://photos.prnewswire.com/prnh/20140911/647229 )
Summary of the Chemotherapy-induced Nausea and Vomiting (CINV) Market Report can be accessed on the website at: https://www.alliedmarketresearch.com/cinv-market
Increase in adoption of chemotherapeutic drugs is directly linked to the growth of the CINV drugs market. It is estimated that in 2016, approximately 1.6 million new cases of cancer will be diagnosed with breast, lung, and bronchus cancer. It is observed that approximately 35% of patients experienced nausea within 24 hours of chemotherapy, while 54% suffered from nausea and 34% experienced vomiting after 24 hours.
Growth in number of patients undergoing chemotherapy drugs treatment and introduction of new drug delivery methods to improve patient compliance are the major factors that significantly impact the growth of the CINV market. At present, pharmaceutical companies are increasingly investing in the R&D of CINV drugs to offer better chemotherapy drugs and increase their market share.
According to Sriram Radhakrishnan (Team Lead, Healthcare Research) at Allied Market Research, "The needle free, painless, and cost-effective transdermal delivery system is expected to witness increase in demand in global CINV market."
KEY FINDINGS OF THE STUDY
The North American market has witnessed a significant growth in the recent years. Presently, it is the largest regional market for CINV drugs and an its market share is anticipated by 2022. Asia-Pacific is the fastest growing market due to increase in number of cancer population, high incidences of gastroenteritis and other diseases that lead to nausea and vomiting. This region boosts up the demand for antiemetic drug due to growth in demand for CINV drugs and is expected to fuel the market growth in this region.
Partnership and collaboration is the key strategy adopted by companies to strengthen their position in the market. The key major players in the global chemotherapy-induced nausea and vomiting drugs are GlaxoSmithKline plc, Helsinn Holding S.A., Heron Therapeutics, Inc., Merck & Co., Inc., and Tesaro, Inc.
Summary of similar reports can be viewed at: https://www.alliedmarketresearch.com/life-sciences/Pharmaceuticals-market-report
About Us:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions". AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
Rahul Thakur
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Direct: +1-503-894-6022
Toll Free: +1 (800) 792-5285 (U.S. & Canada)
Fax: +1 (855) 550-5975
E-mail: [email protected]
Web: https://www.alliedmarketresearch.com
Share this article